March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
March Madness — 25% Off — Limited Time
Get All the Market Moving News, Squawk, and Mentorship NOW
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Champions Oncology
(NASDAQ:CSBR)
Intraday
$4.90
-0.13
[-2.58%]
After-Hours
$5.65
0.75
[15.31%]
Get Report
Watch
Perks
Buy
Compare Brokers
$4.90
-0.13
[-2.58%]
At close: Mar 28
$5.65
0.75
[15.31%]
After Hours: 7:15PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Champions Oncology Stock (NASDAQ:CSBR)
Champions Oncology Stock (NASDAQ: CSBR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 13, 2024
Craig-Hallum Downgrades Champions Oncology to Hold
Benzinga Newsdesk
-
Mar 13, 2024, 8:21AM
Tuesday, March 12, 2024
Champions Oncology: Q3 Earnings Insights
Benzinga Insights
-
Mar 12, 2024, 4:45PM
Champions Oncology Q3 Adj $(0.16) Misses $(0.15) Estimate, Sales $12.02M Miss $13.48M Estimate
Benzinga Newsdesk
-
Mar 12, 2024, 4:41PM
Earnings Scheduled For March 12, 2024
Benzinga Insights
-
Mar 12, 2024, 5:35AM
Monday, March 11, 2024
Earnings Outlook For Champions Oncology
Benzinga Insights
-
Mar 11, 2024, 2:00PM
Tuesday, January 16, 2024
Insiders Buying Solid Biosciences And 2 Other Stocks
Avi Kapoor
-
Jan 16, 2024, 6:17AM
Wednesday, January 10, 2024
Insiders Buying Tilly's And 2 Other Stocks
Avi Kapoor
-
Jan 10, 2024, 6:53AM
Tuesday, December 12, 2023
Recap: Champions Oncology Q2 Earnings
Benzinga Insights
-
Dec 12, 2023, 4:15PM
Champions Oncology Revises Fiscal Year 2024 Revenue Guidance To Be Generally In-Line With Last Year's Results
Benzinga Newsdesk
-
Dec 12, 2023, 4:07PM
Champions Oncology Q2 EPS $(0.15) Down From $0.01 YoY, Sales $11.60M Down From $14.28M YoY
Benzinga Newsdesk
-
Dec 12, 2023, 4:04PM
Earnings Scheduled For December 12, 2023
Benzinga Insights
-
Dec 12, 2023, 5:32AM
Johnson Controls, Oracle And 3 Stocks To Watch Heading Into Tuesday
Avi Kapoor
-
Dec 12, 2023, 3:18AM
Investor Optimism Improves Further Ahead Of Inflation Data; Dow Gains For Third Straight Day
Avi Kapoor
-
Dec 12, 2023, 2:22AM
Thursday, November 02, 2023
Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation And ATS Certification
Benzinga Newsdesk
-
Nov 2, 2023, 8:51AM
Tuesday, October 17, 2023
Champions Oncology Announces The Addition Of Brady Davis As President
Benzinga Newsdesk
-
Oct 17, 2023, 8:32AM
Friday, September 22, 2023
Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5
Benzinga Newsdesk
-
Sep 22, 2023, 11:40AM
Wednesday, September 13, 2023
Champions Oncology Q1 EPS $(0.16) Misses $(0.10) Estimate, Sales $12.60M Miss $13.06M Estimate
Benzinga Newsdesk
-
Sep 13, 2023, 4:03PM
Earnings Scheduled For September 13, 2023
Benzinga Insights
-
Sep 13, 2023, 5:02AM
Tuesday, September 12, 2023
Earnings Outlook For Champions Oncology
Benzinga Insights
-
Sep 12, 2023, 10:01AM
Tuesday, August 01, 2023
Champions Oncology Announces A Multi-Year Agreement And Strategic Collaboration With BioVolume To Transform Reproducibility In Preclinical Oncology Efficacy Studies
Happy Mohamed
-
Aug 1, 2023, 8:50AM
Tuesday, July 25, 2023
Champions Oncology Earnings Perspective: Return On Capital Employed
Benzinga Insights
-
Jul 25, 2023, 10:46AM
Monday, July 24, 2023
Champions Oncology Q4 Adj EPS $(0.17) Misses $(0.12) Estimate, Sales $13.07M Beat $12.86M Estimate
Benzinga Newsdesk
-
Jul 24, 2023, 4:12PM
Earnings Scheduled For July 24, 2023
Benzinga Insights
-
Jul 24, 2023, 4:48AM
Friday, July 21, 2023
Champions Oncology's Earnings: A Preview
Benzinga Insights
-
Jul 21, 2023, 1:01PM
Monday, April 17, 2023
Champions Oncology Launches Its Therapeutic Discovery And Development Platform Into A Wholly Owned Subsidiary Named Corellia AI
Benzinga Newsdesk
-
Apr 17, 2023, 8:34AM
Wednesday, April 05, 2023
Champions Oncology Announces $5M Stock Repurchase Program
Happy Mohamed
-
Apr 5, 2023, 9:58AM
Wednesday, March 22, 2023
$5M Bet On Pyxis Oncology? Check Out These 4 Penny Stocks Insiders Are Buying
Lisa Levin
-
Mar 22, 2023, 7:21AM
Wednesday, March 15, 2023
Champions Oncology Q3 EPS $(0.16) Misses $(0.03) Estimate, Sales $12.77M Miss $13.13M Estimate
Happy Mohamed
-
Mar 15, 2023, 3:57PM
Earnings Scheduled For March 15, 2023
Benzinga Insights
-
Mar 15, 2023, 4:41AM
Tuesday, March 14, 2023
Champions Oncology's Earnings: A Preview
Benzinga Insights
-
Mar 14, 2023, 11:02AM
Friday, December 30, 2022
Champions Oncology's Return On Capital Employed Insights
Benzinga Insights
-
Dec 30, 2022, 9:46AM
Thursday, December 15, 2022
Analyzing Champions Oncology's Short Interest
Benzinga Insights
-
Dec 15, 2022, 1:14PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Dec 15, 2022, 12:32PM
Wednesday, December 14, 2022
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Dec 14, 2022, 4:31PM
Tuesday, December 13, 2022
Champions Oncology Q2 EPS $0.01 Down From $0.03 YoY, Sales $14.30M Up From $11.79M YoY
Benzinga Newsdesk
-
Dec 13, 2022, 4:02PM
Thursday, November 10, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Nov 10, 2022, 11:29AM
Friday, September 16, 2022
Why ZW Data Action Technologies Jumped 37%; Here Are 71 Biggest Movers From Yesterday
Lisa Levin
-
Sep 16, 2022, 4:38AM
Thursday, September 08, 2022
Champions Oncology Q1 EPS $(0.02) Misses $0.01 Estimate, Sales $13.74M Beat $13.19M Estimate
Michael Horton
-
Sep 8, 2022, 4:01PM
Earnings Scheduled For September 8, 2022
Benzinga Insights
-
Sep 8, 2022, 5:26AM
Wednesday, September 07, 2022
Earnings Preview For Champions Oncology
Benzinga Insights
-
Sep 7, 2022, 10:10AM
Thursday, July 21, 2022
Champions Oncology Q4 EPS $(0.02) Misses $0.02 Estimate, Sales $12.90M Beat $12.72M Estimate
Michael Horton
-
Jul 21, 2022, 4:02PM
Earnings Scheduled For July 21, 2022
Benzinga Insights
-
Jul 21, 2022, 4:41AM
Wednesday, July 20, 2022
A Preview Of Champions Oncology's Earnings
Benzinga Insights
-
Jul 20, 2022, 2:05PM
Tuesday, May 31, 2022
Champions Oncology Announces A Partnership With Cyclica To Develop Small Molecule Therapeutics; Terms Not Disclosed
Benzinga Newsdesk
-
May 31, 2022, 8:34AM
Monday, March 21, 2022
Here's How Much You Would Have Made Owning Champions Oncology Stock In The Last 5 Years
Benzinga Insights
-
Mar 21, 2022, 12:01PM
Wednesday, March 16, 2022
Champions Oncology Earnings Perspective: Return On Capital Employed
Benzinga Insights
-
Mar 16, 2022, 11:04AM
Tuesday, March 15, 2022
Earnings Scheduled For March 15, 2022
Benzinga Insights
-
Mar 15, 2022, 4:51AM
Monday, March 14, 2022
Earnings Preview For Champions Oncology
Benzinga Insights
-
Mar 14, 2022, 10:04AM
Thursday, January 20, 2022
Champions Oncology Announces Partnership With Fannin Innovation To Jointly Develop Therapeutic Raptamer Drug Conjugates
Bill Haddad
-
Jan 20, 2022, 8:44AM
Tuesday, January 04, 2022
Champions Oncology Announces Partnership With Alloy Therapeutics To Develop Therapeutic Monoclonal Antibodies For Use In ADC Programs
Bill Haddad
-
Jan 4, 2022, 8:37AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch